GSK India has launched Jemperli and Zejula for gynaecological cancers, marking its return to oncology a decade after ...

Don’t Miss These Signs Cancer is one of the leading causes of death worldwide, and many people often overlook or dismiss early warning signs. While some symptoms are widely recognized, others are more ...

Bhushan Akshikar, Managing Director of GSK India, said the company is committed to making these therapies accessible through a tiered pricing strategy and a comprehensive patient support program ...

Endometrial cancer risk is rising, especially among premenopausal women, with diet and lifestyle factors playing a central ...

GlaxoSmithKline Pharmaceuticals said it is bringing in Jemperli and Zejula to India, marking its re-entry into the cancer ...

At around 2.14 PM, GSK Pharma was trading 0.28% higher at ₹2,806.70 per piece, against the previous close of ₹2,798.80 on NSE.

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies ...

GlaxoSmithKline Pharmaceuticals has launched Jemperli and Zejula in India, pioneering precision therapies for gynaecological ...

GSK enters oncology with Jemperli & Zejula for gynaecological cancers in India. Advanced therapies address unmet needs in ...

Jemperli is the first and only approved programmed death receptor-1 (PD-1) immunotherapy for the second-line treatment of ...